Publication Records

ŠTIKA, Jiří, Michaela PEŠOVÁ, Kateřina STAŇO KOZUBÍK, Magdalena SKALNÍKOVÁ, Lenka DOSTÁLOVÁ, Tomas LOJA, Lenka RADOVÁ, Veronika PALUŠOVÁ, Kamila RÉBLOVÁ, Zuzana VRZALOVÁ, Ivona BLAHÁKOVÁ, Jakub TRIZULJAK, Stjepan ULDRIJAN, Jan BLATNÝ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study. British journal of haematology. Hoboken: Wiley-Blackwell, 2024, 9 pp. ISSN 0007-1048. Available from: https://dx.doi.org/10.1111/bjh.19694.

PESCHELOVÁ, Helena, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

LADUNGOVÁ, Adriana, Helena PESCHELOVÁ, Lenka DOSTÁLOVÁ, Yusuf LODHI, Narendra Varma GOTTUMUKKALA, Jiří MAYER and Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Funkční efekt nově identifikované varianty v genu CYCS u rodiny s trombocytopenií typu 4. In 23. Pražské hematologické dny, Praha. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

GOTTUMUKKALA, Narendra Varma, Aneta LEDEREROVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models. In EHA Meeting – 5th European CAR T-cell Meeting, Rotterdam, Nizozemsko. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Nově identifikovaná varianta v genu CYCS u rodiny s trombocytopenií typu 4 a její funkční dopad. In 25. celostátní konference DNA diagnostiky. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Petra SEDLÁKOVÁ, Radim SONNEK, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu. (A variant in the CYCS gene causing thrombocytopenia 4 increases caspase activity.). In 56. Výroční cytogenomická konference, Ostrava. 2023.

DOSTÁLOVÁ, Lenka, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Narendra Varma GOTTUMUKKALA, Yusuf LODHI and Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In Annual PhD conference Biomedical sciences, Brno. 2022.

GOTTUMUKKALA, Narendra Varma, Veronika MANČÍKOVÁ, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI, Jan VERNER and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In XVII. Myeloma and Cell Therapy Workshop, Ostrava. 2022.

GOTTUMUKKALA, Narendra Varma, Veronika MANČÍKOVÁ, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI, Jan VERNER and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In Annual PhD conference Biomedical sciences, Brno. 2022.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Veronika MANČÍKOVÁ and Michal ŠMÍDA. CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

LEDEREROVÁ, Aneta, Lenka DOSTÁLOVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Martin ČULEN, Tomáš LOJA, Jan VERNER, Šárka POSPÍŠILOVÁ, Michal ŠMÍDA and Veronika MANČÍKOVÁ. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, vol. 9, No 8, p. 1-8. ISSN 2051-1426. Available from: https://dx.doi.org/10.1136/jitc-2021-002352.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Tomáš LOJA, Jan VERNER, Šárka POSPÍŠILOVÁ, Veronika MANČÍKOVÁ and Michal ŠMÍDA. In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

PESCHELOVÁ, Helena, Lenka DOSTÁLOVÁ, Veronika KOZLOVÁ, Aneta LEDEREROVÁ, Václav HEJRET and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.